REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Research/Investigating Angiotensin-(1-7) in Treating Obesity and Insulin Resistance
Back to Research Library

Investigating Angiotensin-(1-7) in Treating Obesity and Insulin Resistance

May 25, 2026
Share
Emerging Research

Based on emerging research. These findings are promising but require further validation.

About This Analysis

This article is an AI-assisted summary of a recently published news item or clinical trial listing. It is intended to provide a quick, accessible overview for the peptide research community. For full accuracy, always refer to the original source linked below.

Investigating Angiotensin-(1-7) in Treating Obesity and Insulin Resistance

A new clinical trial aims to shed light on how a specific peptide, angiotensin-(1-7), can influence metabolism and insulin resistance in obese individuals. This study, sponsored by Vanderbilt University, could provide critical insights into potential therapeutic applications for metabolic disorders such as obesity and type 2 diabetes.

Background

Obesity is increasingly recognized not just as an excess of body fat but also as a condition involving complex hormonal imbalances that can lead to serious health issues like insulin resistance and hypertension. Angiotensin-(1-7) has shown promise in animal studies for its ability to regulate metabolism, potentially reversing these detrimental effects. However, the extent to which this peptide plays a role in human metabolic processes remains unclear.

Vanderbilt University's initiative seeks to bridge this gap by investigating whether angiotensin-(1-7) can improve insulin resistance and other metabolic conditions associated with obesity. This research could pave the way for innovative treatments that leverage peptides like angiotensin-(1-7) to combat metabolic diseases more effectively than current pharmacological options.

Key Details

The clinical trial, identified by ClinicalTrials.gov as NCT02646475, is currently recruiting participants who meet certain criteria related to obesity and insulin resistance. The study will compare the effects of angiotensin-(1-7) against a saline placebo to determine its efficacy in altering metabolic profiles and blood pressure levels.

Participants will be closely monitored throughout the trial period for changes in insulin sensitivity, lipid profiles, and blood pressure readings, among other health indicators. This phase 1 trial is an initial step towards understanding angiotensin-(1-7)'s role in human metabolism, setting the stage for future clinical trials that could lead to FDA-approved peptide therapies.

Key Takeaways

  • Potential Breakthrough: The study aims to confirm whether angiotensin-(1-7) can positively impact insulin resistance and other metabolic conditions associated with obesity.
  • Regulatory Implications: Successful results from this trial could pave the way for further clinical trials, potentially leading to FDA approval of new peptide-based treatments for metabolic diseases.
  • Clinical Application: If proven effective, angiotensin-(1-7) therapy could offer a promising alternative or complement to existing treatments for obesity and type 2 diabetes.
  • Research Impact: This research will contribute valuable data to the growing body of knowledge on how specific peptides influence human metabolism.

What This Means

For researchers and clinicians focused on peptide-based therapies, this study represents an important step forward in understanding the potential clinical applications of angiotensin-(1-7). Positive outcomes could accelerate the development of new treatments for metabolic disorders and enhance our overall comprehension of peptide mechanisms in health and disease. The broader peptide community will be closely watching the results to see if they support further investigation into this promising avenue.

---

Source: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02646475) — Published 2026-05-22

This article is for informational purposes only and does not constitute medical advice.

Editor's Note

This analysis was generated using AI tools and reviewed by the Peptide Contacts editorial team. While we strive for accuracy, AI-generated content may contain errors or omissions. We encourage readers to review the original source for complete details, methodology, and data.

Peptide Contacts provides curated research summaries for informational purposes only. This content does not constitute medical advice. Always consult a qualified healthcare provider before making any health decisions.

Comments

Sign in to join the discussion

This article was generated using AI and may contain inaccuracies. It is provided for informational purposes only and does not constitute medical advice. Always verify information with the original source and consult a qualified healthcare provider before making any health decisions.